Lineage Cell Therapeutics, Inc.
$1.65
▼
-1.26%
2026-04-21 07:50:01
www.lineagecell.com
ASE: LCTX
Explore Lineage Cell Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$410.99 M
Current Price
$1.65
52W High / Low
$2.09 / $0.4
Stock P/E
—
Book Value
$0.18
Dividend Yield
—
ROCE
-21.52%
ROE
-1.05%
Face Value
—
EPS
$-0.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
72
Beta
1.8
Debt / Equity
5.58
Current Ratio
5.2
Quick Ratio
5.2
Forward P/E
-19.1
Price / Sales
25.33
Enterprise Value
$314.08 M
EV / EBITDA
-14.9
EV / Revenue
21.58
Rating
None
Target Price
$4.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
| 2. | KalVista Pharmaceuticals, Inc. | $20.87 | — | $1.07 B | — | -89% | -121.5% | $21.3 / $9.83 | $-0.05 |
| 3. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
| 4. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
| 5. | Entera Bio Ltd. | $1.34 | — | $62.47 M | — | -83.6% | -1.08% | $3.22 / $0.91 | $0.28 |
| 6. | Shattuck Labs, Inc. | $7.88 | — | $538.88 M | — | -61.34% | -60.25% | $7.68 / $0.71 | $1.3 |
| 7. | AN2 Therapeutics, Inc. | $3.62 | — | $129.78 M | — | -71.59% | -52.14% | $6.91 / $1 | $1.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 6.61 M | 3.68 M | 2.77 M | 1.5 M | 2.87 M | — |
| Operating Profit | -6.55 M | -3.79 M | -4.94 M | -6.5 M | -5.11 M | — |
| Net Profit | 0.85 M | -29.78 M | -30.46 M | -4.14 M | -3.27 M | — |
| EPS in Rs | 0 | -0.12 | -0.12 | -0.02 | -0.01 | -0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 14.56 M | 9.5 M | 8.95 M | 14.7 M |
| Operating Profit | -21.78 M | -21.48 M | -24.73 M | -22.52 M |
| Net Profit | -63.53 M | -18.61 M | -21.49 M | -26.27 M |
| EPS in Rs | -0.26 | -0.07 | -0.09 | -0.11 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 112.58 M | 113.22 M | 101.02 M | 123.66 M |
| Total Liabilities | 69.24 M | 36.21 M | 39 M | 51.73 M |
| Equity | 44.55 M | 78.38 M | 63.42 M | 73.34 M |
| Current Assets | 59.16 M | 51 M | 38.44 M | 60 M |
| Current Liabilities | 11.37 M | 13.98 M | 17.96 M | 18.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.92 M | -23.09 M | -28.57 M | 1.06 M |
| Investing CF | -13.46 M | -2.31 M | 46.45 M | -46.16 M |
| Financing CF | 26.95 M | 35.86 M | 6.42 M | 1.63 M |
| Free CF | -19.44 M | -23.66 M | -29.24 M | 0.65 M |
| Capex | -0.52 M | -0.56 M | -0.67 M | -0.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 6.19% | -39.16% | — | — |
| Earnings Growth % | 13.39% | 18.22% | — | — |
| Profit Margin % | -195.9% | -240.2% | -178.69% | — |
| Operating Margin % | -226.11% | -276.5% | -153.17% | — |
| Gross Margin % | 96.48% | 92.5% | 95.05% | — |
| EBITDA Margin % | -219.7% | -268.76% | -148.22% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.